BVMed proposes wound care law amendments:
This article was originally published in Clinica
Executive Summary
Even though modern wound care products are a proven means of saving costs in the long run, they are often rejected simply because of the initial price per item, says Joachim Schmitt, director of the German medical device industry association (BVMed). Speaking at a press conference of the German association for wound care, he said that traditional wound care products lead to longer healing times for patients, which in turn lead to higher costs for the health insurers. Among the proposals put forward by Mr Schmitt to promote the use of innovative products were the removal or easing of budgeting applied to procedures for the treatment of chronic wounds, and the inclusion of chronic wound care products in a special category for reimbursement.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.